A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy

Mitochondrial Myopathy Clinical Trial

Official title:
Randomized, Double-blinded, Placebo-controlled Study Evaluating the Efficacy of Nicotinamide Riboside (NR) - a Vitamin B3 Derivative - for Treatment of Mitochondrial Myopathy Disorder

Status Recruiting

Clinical Trial Summary

The purpose of this study is to determine the effects of Nicotinamide Riboside (NR) supplement in adult-onset symptoms of mitochondrial myopathy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05590468
Study type	Interventional
Source	Mayo Clinic
Contact	Alexandra Miller
Phone	507-293-1139
Email	miller.alexandra@mayo.edu
Status	Recruiting
Phase	Phase 2
Start date	May 26, 2023
Completion date	November 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00004770` - Pilot Compassionate Use Study of Thioctic Acid Treatment in Mitochondrial Myopathy	N/A
Completed	`NCT02895789` - Oxidative Capacity and Exercise Tolerance in Ambulatory SMA
Recruiting	`NCT00457314` - The Effects of Exercise Versus Inactivity on People With Mitochondrial Muscle Disease	Phase 2
Completed	`NCT02367014` - Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy	Phase 1/Phase 2
Completed	`NCT00004353` - Study of the Metabolism of Pyruvate and Related Problems in Patients With Lactic Acidemia	N/A